PMPCA

Across TCGA pan-cancer cohorts, PMPCA mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PMPCA data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PMPCA mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PMPCA expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, GBM, and LSCC are the cancer types where PMPCA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.964	0.708	.001	13	view →
GBM	DFS	Median	All	0.669	0.823	.020	10	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.908	.026	3	view →
CCRCC	DFS	Quartile	II,III,IV	0.418	0.765	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PMPCA–LUAD (DFS)

Open the LUAD breakdown →